PrimeRFP SCOUT · Federal Contract Recompete Brief

HT942523F0048FISCAL YEAR 22-23 BREAST CANCER research — Leidos, Inc

Leidos, Inc holds $3.2B across 1,081 federal awards, concentrated at Department of Defense (DOD). This PIID sits alongside 5 related awards under parent HT942523D0002. PoP ended Feb 22, 2024 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Army Med Res Acq Activity

Awarding office

Leidos, Inc

Recipient

Feb 22, 2024

PoP end

$785K

Obligated

$1.2M

Potential

541990

NAICS

R408

PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Leidos, Inc — $90

Contract facts

Federal

Contract numberHT942523F0048

Also listed asHT9425-23-F-0048

Also listed asHT942523D0002-HT942523F0048

AgencyArmy Med Res Acq Activity

Awarding officeArmy Med Res Acq Activity

Awarding agencyDepartment of Defense (DOD)

Funding agencyDepartment of Defense (DOD)

IncumbentLeidos, Inc

CAGE5UTE2

UEIQLNMVC12KWY3

NAICS541990

No full NAICS 541990 intel page yet. Browse NAICS intelligence

PSCR408

Parent IDIQ / IDVHT942523D0002

Place of performanceFREDERICK MD

Pricing typeCost Plus Fixed Fee

Extent competedFull And Open Competition

Related solicitationW81XWH22R0025

PoP startFeb 23, 2023

PoP end (current)Feb 22, 2024

Obligated$785K

Current value$1.2M

Potential value$1.2M

FISCAL YEAR 22-23 BREAST CANCER RESEARCH PROGRAM GENERAL SUPPORT, PRE-APPLICATION SCREENING AND PROGRAMMATIC REVIEW is a federal award for Army Med Res Acq Activity held by Leidos, Inc. Estimated value $1.2M ($785K obligated). Current period of performance ends Feb 22, 2024. Place of performance: FREDERICK MD. Related solicitation W81XWH22R0025.

FISCAL YEAR 22-23 BREAST CANCER RESEARCH PROGRAM GENERAL SUPPORT, PRE-APPLICATION SCREENING AND PROGRAMMATIC REVIEW

Recompete timing

Public

● Past PoP end (911 days ago)

Current PoP ended Feb 22, 2024 (911 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Leidos, Inc — $3.2B obligated across 1,081 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).

% of firm-wide obligated ($3.2B) · all agencies · Top 4 shown (97%); remaining ~3% is other agencies.

Department of Defense (DOD)$1.2B · 38%National Aeronautics and Space Administration (NASA)$922.8M · 29%General Services Administration (GSA)$847.1M · 26%Department of Transportation (DOT)$140.6M · 4%

Open full company profile →

Related awards

Same parent · incumbent

W912DR21F0329

FIELD SCALE TREATABILITY STUDY, PP AND ROD TNT/NRB AT THE FNOD

$1.2M

Aug 27, 2026

FA825121F0146

F-16 AIS/PSI ENGINEERING SUPPORT.

$6.0M

Aug 31, 2026

FA441925F0130

ARCHITECT-ENGINEERING ENVIRONMENTAL SERVICES 2023 TO SUPPORT ENVIRONMENTAL PROGRAMS WORLDW…

$380K

Aug 31, 2026

N6264521F0279

ATEAM RESEARCH

$11.9M

Sep 9, 2026

W912DR21F0348

MARTINSBURG PFAS REMEDIAL INVESTIGATION. MARTINSBURG AIR NATIONAL GUARD BASE, WV.

$7.2M

Sep 11, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract HT942523F0048?

HT942523F0048 (FISCAL YEAR 22-23 BREAST CANCER research) is a Army Med Res Acq Activity award with a potential value of $1.2M, currently held by Leidos, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is HT9425-23-F-0048?

HT9425-23-F-0048 is the dashed form of PIID HT942523F0048 (FISCAL YEAR 22-23 BREAST CANCER research), held by Leidos, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded HT942523F0048?

Army Med Res Acq Activity awarded HT942523F0048 to Leidos, Inc (potential $1.2M).

Who is the incumbent on HT942523F0048?

Leidos, Inc is the incumbent with $3.2B across 1081 related awards in SCOUT’s public footprint. The current period of performance ends Feb 22, 2024.

When does Leidos, Inc’s HT942523F0048 come up for recompete?

SCOUT tracks a period-of-performance end of Feb 22, 2024. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jun 26, 2026 · refreshed monthlyLatest procurement action May 10, 2024